Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic ...

"We are excited about the prospects of a novel treatment option for patients who are suffering from pulmonary arterial hypertension," said Dr. John Granton, Director of the Pulmonary Hypertension (PH) ...

Hypertension affects 1 in 8 adults aged between 20 and 40 years. The prevalence of hypertension among adults in India is ...

Addressing sleep-related complaints may enhance symptomatic treatment and management of PAH. Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was ...

Alembic Pharmaceuticals received final USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, designed to treat hypertension. Available in multiple strengths, these capsules ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

These capsules will be available in dosages of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, offering a generic alternative to ...

Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA, it added.

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...